AstraZeneca-BMS Diabetes Deal Done: What’s Next On Biocon’s Oral Insulin?
This article was originally published in PharmAsia News
Executive Summary
AstraZeneca has declined an option agreement from Bristol-Myers Squibb on Indian drug maker Biocon’s oral insulin, raising questions about the fate of the candidate Biocon hopes will be a blockbuster.